Printer Friendly

BIOMUNE SYSTEMS, INC. ANNOUNCES PRECLINICAL DRUG FOR PREVENTING AND TREATING CRYPTOSPORIDIOSIS IN ANIMALS

 SALT LAKE CITY, April 12 /PRNewswire/ -- Biomune Systems, Inc., a biogenetic company specializing in drugs that fight gastrointestinal diseases, announced today a preclinical drug that has proven to be effective in preventing and treating cryptosporidiosis in animals. David Derrick, president of the company, stated that Biomune is in the process within the next four weeks of submitting its Investigative New Drug application to the Food and Drug Administration to commence clinical trials on humans who suffer from cryptosporidiosis. It was this same disease that recently contaminated the tap-water in Milwaukee and caused severe diarrhea to many residents in the Milwaukee area.
 Cryptosporidiosis is caused by a cryptosporidia protozoan that infects the intestinal tract of its host. Cryptosporidia has been recognized as an animal disease since the turn of the century. However, it was not until the past 10 years with the advent of the AIDS epidemic, that cryptosporidiosis was even recognized to be a human disease. The reason for this is that cryptosporidiosis is one of the foremost killers of AIDS patients. Since this discovery was made, it has now been determined that many people have suffered from cryptosporidiosis; it just simply has been misdiagnosed. In normal hosts the patient suffers from profuse diarrhea and cholera like symptoms for a period of about one week. In the immune impaired patient the symptoms may last for months or even years, eventually leading to death. Currently, there is no known accepted treatment for cryptosporidiosis.
 According to Derrick, Biomune's USDA approved drug has treated thousands of animals for cryptosporidia worldwide over the past seven years.
 Biomune's drugs are covered by patents for a process to produce large Ig proteins (immunoglobulins) on a production basis. These Ig proteins which are derived from a natural organic source, are the soldiers that fight off disease in humans. They could neutralize a wide range of disease viruses and bacteria such as ulcers, various gastroenterological diseases, travelers' diarrhea, AIDS related ailments, and even help immune impaired cancer patients.
 -0- 4/12/93
 /CONTACT: David Derrick, president of Biomune Systems, Inc., 801-364-5850/


CO: Biomune Systems, Inc. ST: Utah IN: MTC SU:

TS -- NY056 -- 4807 04/12/93 13:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 12, 1993
Words:361
Previous Article:VOLUNTARY RECALL OF CHERUBS 'RETRIEVERS' ANNOUNCED
Next Article:UNIVERSITY OF SAN DIEGO'S LEADING ECONOMIC INDICATORS UP IN FEBRUARY
Topics:


Related Articles
BIOMUNE SYSTEMS, INC. ANNOUNCES PRECLINICAL DRUG FOR E. COLI
BIOMUNE SYSTEMS, INC. BOARD OF DIRECTORS APPROVES STOCK SPLIT, DIVIDENDS
GALAGEN SIGNS TECHNOLOGY LICENSING AGREEMENT WITH NESTLE S.A.
CORTECH BEGINS PRECLINICAL DEVELOPMENT OF COMPOUNDS FOR SULFA ALLERGY TREATMENT IN AIDS PATIENTS
AGOURON REPORTS INTERIM RESULTS FROM PHASE I STUDIES OF ANTI-TUMOR DRUG AG331
BIOMUNE SYSTEMS, INC. FORMS SUBSIDIARY TO ENTER NUTRICEUTICAL MARKET
Biomune Systems, Inc. and Donlar Corporation Announce Business Combination.
Biomune Systems, Inc. Announces Donlar Corporation Will Transfer Certain Assets in Exchange for Biomune Common Stock.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters